ondansetron has been researched along with Diarrhea in 55 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS-D)." | 9.41 | Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. ( Akbar, A; Aziz, Q; Barnard, L; Brindle, R; Corsetti, M; Dinning, PG; Eugenicos, M; Farmer, A; Farrin, AJ; Ford, AC; Fried, R; Gunn, D; Holloway, I; Houghton, L; Kapur, K; Mclaughlin, J; Sanders, D; Scott, M; Spiller, R; Topan, R; Trudgill, N; Whorwell, P, 2023) |
| "Previous, small studies have suggested that ondansetron has beneficial effects in diarrhea-predominant irritable bowel syndrome (IBS-D)." | 9.34 | Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. ( Abramson, D; Barton, G; Davidson, E; Fathi, R; Harris, MS; Kalfus, I; Plasse, TF; Raday, G, 2020) |
| "After drug administration, 22 (73%) of the 30 patients in the ondansetron group had complete cessation of vomiting compared with 7 (23%) of the 31 patients in the placebo group (RR 0." | 9.30 | Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. ( Chanh, TQ; My, PT; Rang, NN; Tien, TTM, 2019) |
| "To evaluate the role of oral ondansetron in facilitating successful rehydration of under-5-year-old children suffering from acute diarrhea with vomiting and some dehydration." | 9.22 | Oral Ondansetron in Management of Dehydrating Diarrhea with Vomiting in Children Aged 3 Months to 5 Years: A Randomized Controlled Trial. ( Batra, P; Bhattacharya, SK; Danewa, AS; Gupta, P; Shah, D, 2016) |
| " Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation." | 9.14 | Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study. ( Finkelstein, Y; Freedman, SB; Nava-Ocampo, AA; Powell, EC, 2010) |
| "Ondansetron was effective in reducing the emesis from gastroenteritis during the ED phase of oral rehydration and in lowering the rates of intravenous fluid administration and hospital admission." | 9.10 | A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. ( Kozinetz, CA; Moro-Sutherland, D; Ramsook, C; Sahagun-Carreon, I, 2002) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 9.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "At several out-of-hours services primary care, a single dose of ondansetron was compared with standard care (oral rehydration solution (ORS)) in young children with gastroenteritis and persistent vomiting." | 8.12 | [No place for ondansetron in young children with gastroenteritis and persistent vomiting]. ( Wichers, IM, 2022) |
| "Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge." | 8.12 | Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis. ( Bhatt, SR; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, K; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2022) |
| "We determine whether single-dose oral ondansetron administration to children with vomiting as a result of acute gastroenteritis without dehydration reduces administration of intravenous fluid rehydration." | 7.91 | Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial. ( Ali, N; Bhutta, ZA; Dawoud, F; Freedman, SB; Soofi, SB; Willan, AR; Williamson-Urquhart, S; Xie, J, 2019) |
| "Chemotherapeutic agents, including 5-fluorouracil (5-FU), frequently cause intestinal mucositis resulting in severe diarrhoea and morphological mucosal damage." | 7.79 | 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. ( Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M, 2013) |
| " Ondansetron has been well tolerated when used to control nausea and vomiting in patients receiving chemotherapy." | 7.73 | Ondansetron for acute gastroenteritis in children. ( Goldman, RD; Mehta, S, 2006) |
| "To assess the value of ondansetron in a patient with intractable nausea, abdominal pain and diarrhoea unrelated to cancer chemotherapy or radiotherapy." | 7.68 | Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron. ( Evans, JE, 1993) |
| "Ondansetron is a new 5-HT3-antagonist with antiemetic properties." | 6.67 | The effect of ondansetron on radiation-induced emesis and diarrhoea. ( Franzén, L; Henriksson, R; Israelsson, G; Lomberg, H; Zackrisson, B, 1992) |
| "There is a clear unmet need for new treatments in irritable bowel syndrome with diarrhea (IBS-D)." | 5.56 | Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation? ( Melchior, C; Simrén, M, 2020) |
| "Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS-D)." | 5.41 | Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. ( Akbar, A; Aziz, Q; Barnard, L; Brindle, R; Corsetti, M; Dinning, PG; Eugenicos, M; Farmer, A; Farrin, AJ; Ford, AC; Fried, R; Gunn, D; Holloway, I; Houghton, L; Kapur, K; Mclaughlin, J; Sanders, D; Scott, M; Spiller, R; Topan, R; Trudgill, N; Whorwell, P, 2023) |
| "Previous, small studies have suggested that ondansetron has beneficial effects in diarrhea-predominant irritable bowel syndrome (IBS-D)." | 5.34 | Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. ( Abramson, D; Barton, G; Davidson, E; Fathi, R; Harris, MS; Kalfus, I; Plasse, TF; Raday, G, 2020) |
| "After drug administration, 22 (73%) of the 30 patients in the ondansetron group had complete cessation of vomiting compared with 7 (23%) of the 31 patients in the placebo group (RR 0." | 5.30 | Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. ( Chanh, TQ; My, PT; Rang, NN; Tien, TTM, 2019) |
| "To evaluate the role of oral ondansetron in facilitating successful rehydration of under-5-year-old children suffering from acute diarrhea with vomiting and some dehydration." | 5.22 | Oral Ondansetron in Management of Dehydrating Diarrhea with Vomiting in Children Aged 3 Months to 5 Years: A Randomized Controlled Trial. ( Batra, P; Bhattacharya, SK; Danewa, AS; Gupta, P; Shah, D, 2016) |
| " Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation." | 5.14 | Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study. ( Finkelstein, Y; Freedman, SB; Nava-Ocampo, AA; Powell, EC, 2010) |
| "Ondansetron was effective in reducing the emesis from gastroenteritis during the ED phase of oral rehydration and in lowering the rates of intravenous fluid administration and hospital admission." | 5.10 | A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. ( Kozinetz, CA; Moro-Sutherland, D; Ramsook, C; Sahagun-Carreon, I, 2002) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 5.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "The effects of ondansetron and placebo on fasting and postprandial colonic tone and motility in 10 patients with carcinoid diarrhea were compared using a manometry-barostat assembly positioned in the upper descending colon." | 5.07 | A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. ( Camilleri, M; Kvols, LK; von der Ohe, MR, 1994) |
| "Ondansetron is the only intervention that revealed an effect on the cessation of vomiting, on preventing hospitalizations, and in reducing the need for intravenous rehydration." | 5.05 | Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis. ( Acosta-Reyes, J; Florez, ID; Niño-Serna, LF; Veroniki, AA, 2020) |
| " Ondansetron (orally or intravenously) may be effective in decreasing the rate of vomiting, improving the success rate of oral hydration, preventing the need for i." | 4.86 | The management of children with gastroenteritis and dehydration in the emergency department. ( Barata, IA; Brown, KM; Colletti, JE; Ishimine, P; Sharieff, GQ, 2010) |
| "Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge." | 4.12 | Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis. ( Bhatt, SR; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, K; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2022) |
| "At several out-of-hours services primary care, a single dose of ondansetron was compared with standard care (oral rehydration solution (ORS)) in young children with gastroenteritis and persistent vomiting." | 4.12 | [No place for ondansetron in young children with gastroenteritis and persistent vomiting]. ( Wichers, IM, 2022) |
| "We determine whether single-dose oral ondansetron administration to children with vomiting as a result of acute gastroenteritis without dehydration reduces administration of intravenous fluid rehydration." | 3.91 | Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial. ( Ali, N; Bhutta, ZA; Dawoud, F; Freedman, SB; Soofi, SB; Willan, AR; Williamson-Urquhart, S; Xie, J, 2019) |
| "Chemotherapeutic agents, including 5-fluorouracil (5-FU), frequently cause intestinal mucositis resulting in severe diarrhoea and morphological mucosal damage." | 3.79 | 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. ( Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M, 2013) |
| " Ondansetron has been well tolerated when used to control nausea and vomiting in patients receiving chemotherapy." | 3.73 | Ondansetron for acute gastroenteritis in children. ( Goldman, RD; Mehta, S, 2006) |
| "Our aim was to study the involvement of 5-hydroxytryptamine (5-HT)(3) and 5-HT(4) receptors in two models of gastrointestinal transit (GIT) in mice: the 5-hydroxytryptophan (5-HTP)-induced diarrhea and intestinal inflammation produced by an irritant agent, croton oil (CO)." | 3.71 | The involvement of 5-HT3 and 5-HT4 receptors in two models of gastrointestinal transit in mice. ( Alsasua, A; Goicoechea, C; Martín, MI; Pascual, D, 2002) |
| "To assess the value of ondansetron in a patient with intractable nausea, abdominal pain and diarrhoea unrelated to cancer chemotherapy or radiotherapy." | 3.68 | Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron. ( Evans, JE, 1993) |
| "Ondansetron is a new 5-HT3-antagonist with antiemetic properties." | 2.67 | The effect of ondansetron on radiation-induced emesis and diarrhoea. ( Franzén, L; Henriksson, R; Israelsson, G; Lomberg, H; Zackrisson, B, 1992) |
| "There is a clear unmet need for new treatments in irritable bowel syndrome with diarrhea (IBS-D)." | 1.56 | Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation? ( Melchior, C; Simrén, M, 2020) |
| "For moderate dehydration, eight CPGs advocated nasogastric (NG) rehydration in preference to intravenous (IV) rehydration." | 1.35 | Emergency department management of gastro-enteritis in Australia and New Zealand. ( Babl, FE; Borland, M; Schutz, J; Sheriff, N, 2008) |
| "Flushing was not affected." | 1.30 | Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. ( de Vries, EG; Kema, IP; Kleibeuker, JH; Leijsma, MK; Wymenga, AN, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (25.45) | 18.2507 |
| 2000's | 8 (14.55) | 29.6817 |
| 2010's | 24 (43.64) | 24.3611 |
| 2020's | 9 (16.36) | 2.80 |
| Authors | Studies |
|---|---|
| Kishibayashi, N | 1 |
| Miwa, Y | 1 |
| Hayashi, H | 1 |
| Ishii, A | 1 |
| Ichikawa, S | 1 |
| Nonaka, H | 1 |
| Yokoyama, T | 1 |
| Suzuki, F | 1 |
| Wichers, IM | 1 |
| Koza, J | 1 |
| Liebert, A | 1 |
| Hołyńska-Iwan, I | 1 |
| Piskorska, E | 1 |
| Kaczorowski, P | 1 |
| Gunn, D | 4 |
| Topan, R | 1 |
| Barnard, L | 1 |
| Fried, R | 2 |
| Holloway, I | 2 |
| Brindle, R | 1 |
| Corsetti, M | 2 |
| Scott, M | 2 |
| Farmer, A | 2 |
| Kapur, K | 2 |
| Sanders, D | 2 |
| Eugenicos, M | 2 |
| Trudgill, N | 2 |
| Whorwell, P | 5 |
| Mclaughlin, J | 2 |
| Akbar, A | 2 |
| Houghton, L | 2 |
| Dinning, PG | 2 |
| Aziz, Q | 2 |
| Ford, AC | 6 |
| Farrin, AJ | 1 |
| Spiller, R | 5 |
| Lalani, R | 1 |
| Farrin, A | 1 |
| Morris, T | 1 |
| Olivier, C | 1 |
| Kearns, R | 1 |
| Emmanuel, A | 1 |
| Yiannakou, Y | 1 |
| Black, CJ | 2 |
| Houghton, LA | 1 |
| Garsed, K | 3 |
| Lam, C | 3 |
| Singh, G | 3 |
| Lingaya, M | 2 |
| Wahl, V | 2 |
| Niesler, B | 2 |
| Henry, A | 3 |
| Hall, I | 2 |
| Niño-Serna, LF | 1 |
| Acosta-Reyes, J | 1 |
| Veroniki, AA | 1 |
| Florez, ID | 1 |
| Plasse, TF | 2 |
| Barton, G | 1 |
| Davidson, E | 1 |
| Abramson, D | 1 |
| Kalfus, I | 1 |
| Fathi, R | 1 |
| Raday, G | 1 |
| Harris, MS | 1 |
| Melchior, C | 1 |
| Simrén, M | 1 |
| Powell, EC | 2 |
| Roskind, CG | 1 |
| Schnadower, D | 1 |
| Olsen, CS | 1 |
| Casper, TC | 1 |
| Tarr, PI | 1 |
| O'Connell, KJ | 1 |
| Levine, AC | 1 |
| Poonai, N | 1 |
| Schuh, S | 1 |
| Rogers, AJ | 1 |
| Bhatt, SR | 1 |
| Gouin, S | 1 |
| Mahajan, P | 1 |
| Vance, C | 1 |
| Hurley, K | 1 |
| Farion, KJ | 1 |
| Sapien, RE | 1 |
| Freedman, SB | 3 |
| De Puy, F | 1 |
| Kay, GN | 1 |
| Soofi, SB | 1 |
| Willan, AR | 1 |
| Williamson-Urquhart, S | 1 |
| Ali, N | 1 |
| Xie, J | 1 |
| Dawoud, F | 1 |
| Bhutta, ZA | 1 |
| Rees, CA | 1 |
| Nigrovic, LE | 1 |
| Rang, NN | 1 |
| Chanh, TQ | 1 |
| My, PT | 1 |
| Tien, TTM | 1 |
| Hall, IP | 1 |
| Kiesewetter, B | 1 |
| Raderer, M | 1 |
| Chernova, J | 1 |
| Hastings, M | 1 |
| Marciani, L | 2 |
| Barbara, G | 1 |
| Luthra, P | 2 |
| Levy, R | 1 |
| Corbo, J | 1 |
| Prasad, S | 1 |
| Lalani, N | 1 |
| Gaco, D | 1 |
| Danewa, AS | 1 |
| Shah, D | 1 |
| Batra, P | 1 |
| Bhattacharya, SK | 1 |
| Gupta, P | 1 |
| Mathew, JL | 1 |
| Kumar, P | 1 |
| Deswal, S | 1 |
| Schutz, J | 1 |
| Babl, FE | 1 |
| Sheriff, N | 1 |
| Borland, M | 1 |
| Colletti, JE | 1 |
| Brown, KM | 1 |
| Sharieff, GQ | 1 |
| Barata, IA | 1 |
| Ishimine, P | 1 |
| Trepanier, L | 1 |
| Wright, J | 1 |
| Foley, S | 1 |
| Hoad, CL | 1 |
| Totman, JJ | 1 |
| Bush, D | 1 |
| Hartley, C | 1 |
| Armstrong, A | 1 |
| Manby, P | 1 |
| Blackshaw, E | 1 |
| Perkins, AC | 1 |
| Gowland, PA | 1 |
| Spiller, RC | 1 |
| Nava-Ocampo, AA | 1 |
| Finkelstein, Y | 1 |
| Yasuda, M | 1 |
| Kato, S | 1 |
| Yamanaka, N | 1 |
| Iimori, M | 1 |
| Matsumoto, K | 1 |
| Utsumi, D | 1 |
| Kitahara, Y | 1 |
| Amagase, K | 1 |
| Horie, S | 1 |
| Takeuchi, K | 1 |
| Pascual, D | 2 |
| Girón, R | 1 |
| Alsasua, A | 2 |
| Benhamú, B | 1 |
| López-Rodríguez, ML | 1 |
| Martín, MI | 2 |
| Spirko, BA | 1 |
| Mehta, S | 1 |
| Goldman, RD | 1 |
| Wilkes, G | 1 |
| Schwörer, H | 2 |
| Münke, H | 1 |
| Stöckmann, F | 1 |
| Ramadori, G | 2 |
| Bossi, A | 1 |
| Baresi, A | 1 |
| Ballini, A | 1 |
| Bindelli, C | 1 |
| Hartmann, H | 1 |
| von der Ohe, MR | 1 |
| Camilleri, M | 1 |
| Kvols, LK | 1 |
| Evans, JE | 1 |
| Cubeddu, LX | 1 |
| Trujillo, LM | 1 |
| Talmaciu, I | 1 |
| Gonzalez, V | 1 |
| Guariguata, J | 1 |
| Seijas, J | 1 |
| Miller, IA | 1 |
| Paska, W | 1 |
| Khoo, VS | 1 |
| Rainford, K | 1 |
| Horwich, A | 1 |
| Dearnaley, DP | 1 |
| Wymenga, AN | 1 |
| de Vries, EG | 1 |
| Leijsma, MK | 1 |
| Kema, IP | 1 |
| Kleibeuker, JH | 1 |
| Grøndahl, ML | 1 |
| Jensen, GM | 1 |
| Nielsen, CG | 1 |
| Skadhauge, E | 1 |
| Olsen, JE | 1 |
| Hansen, MB | 1 |
| Sinha, PK | 1 |
| Tripathi, M | 1 |
| Ambesh, SP | 1 |
| Bearcroft, CP | 1 |
| Domizio, P | 1 |
| Mourad, FH | 1 |
| André, EA | 1 |
| Farthing, MJ | 1 |
| McCune, JS | 1 |
| Oertel, MD | 1 |
| Pfeifer, D | 1 |
| Houston, SA | 1 |
| Bingham, A | 1 |
| Sawyer, WT | 1 |
| Lindley, CM | 1 |
| Ramsook, C | 1 |
| Sahagun-Carreon, I | 1 |
| Kozinetz, CA | 1 |
| Moro-Sutherland, D | 1 |
| Goicoechea, C | 1 |
| Steadman, CJ | 1 |
| Talley, NJ | 1 |
| Phillips, SF | 1 |
| Zinsmeister, AR | 1 |
| Henriksson, R | 1 |
| Lomberg, H | 1 |
| Israelsson, G | 1 |
| Zackrisson, B | 1 |
| Franzén, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Placebo Controlled Trial to Determine the Efficacy and Mode of Action of Ondansetron in the Treatment of Irritable Bowel Syndrome With Diarrhoea[NCT03555188] | Phase 3 | 80 participants (Actual) | Interventional | 2018-03-29 | Completed | ||
| Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in Emergency Departments in Pakistan[NCT01870635] | Phase 4 | 625 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Prevelane and Short Term Outcome of Hypernatremic Dehydration in Children With Acute Gastroenteritis in Sohag University Hospital[NCT05440162] | 50 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| Effect of Physical Form of Apples on Gastrointestinal Function and Satiety: a MRI Study[NCT03714464] | 31 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Ondansetron vs. Placebo in the Management of Children With Dehydration Due to Acute Gastroenteritis[NCT00691275] | 0 participants (Actual) | Interventional | 2008-09-30 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ondansetron and Diarrhea
| Article | Year |
|---|---|
Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.
Topics: Diarrhea; Double-Blind Method; Feces; Humans; Irritable Bowel Syndrome; Ondansetron; Randomized Cont | 2023 |
Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Dexamethasone; Diarrhea; Dimenhydrinate; Domper | 2020 |
Ondansetron for gastroenteritis in children and adolescents.
Topics: Adolescent; Antiemetics; Child; Diarrhea; Gastroenteritis; Humans; Ondansetron; Vomiting | 2015 |
The management of children with gastroenteritis and dehydration in the emergency department.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dehydration; Diarrhea; Emergency Service, Hospital | 2010 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indol | 2010 |
14 trials available for ondansetron and Diarrhea
| Article | Year |
|---|---|
Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial.
Topics: Antidiarrheals; Clinical Trials, Phase III as Topic; Diarrhea; Double-Blind Method; Humans; Irritabl | 2019 |
Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Defecation; Diarrhea; Double-Blind Method; Female; Gastroin | 2020 |
Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial.
Topics: Antiemetics; Child, Preschool; Dehydration; Diarrhea; Double-Blind Method; Drug Administration Sched | 2019 |
Abnormalities of mucosal serotonin metabolism and 5-HT
Topics: Adult; Cross-Over Studies; Diarrhea; Female; Genotype; Humans; Intestinal Mucosa; Irritable Bowel Sy | 2019 |
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.
Topics: Adult; Cross-Over Studies; Diarrhea; Double-Blind Method; Feces; Female; Humans; Irritable Bowel Syn | 2014 |
Oral Ondansetron in Management of Dehydrating Diarrhea with Vomiting in Children Aged 3 Months to 5 Years: A Randomized Controlled Trial.
Topics: Administration, Oral; Antiemetics; Child, Preschool; Dehydration; Diarrhea; Double-Blind Method; Fem | 2016 |
Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study.
Topics: Child; Child, Preschool; Cohort Studies; Dehydration; Diarrhea; Dose-Response Relationship, Drug; Fe | 2010 |
A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.
Topics: Adult; Aged; Colon; Diarrhea; Double-Blind Method; Eating; Fasting; Female; Gastrointestinal Motilit | 1994 |
Antiemetic activity of ondansetron in acute gastroenteritis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Diarrhea; Female; Fluid Therapy; Gastroenteriti | 1997 |
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
Topics: Acute Disease; Adult; Antiemetics; Diarrhea; Gastrointestinal Diseases; Humans; Lymphatic Metastasis | 1997 |
Efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting in patients following infratentorial surgery: a placebo-controlled prospective double-blind study.
Topics: Adolescent; Adult; Anesthesia Recovery Period; Antiemetics; Cerebellum; Consciousness; Diarrhea; Dou | 1999 |
A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis.
Topics: Acute Disease; Administration, Oral; Child; Child, Preschool; Diarrhea; Double-Blind Method; Female; | 2002 |
Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
Topics: Adult; Aged; Colonic Diseases, Functional; Diarrhea; Double-Blind Method; Female; Gastrointestinal H | 1992 |
The effect of ondansetron on radiation-induced emesis and diarrhoea.
Topics: Abdominal Neoplasms; Adult; Aged; Diarrhea; Female; Humans; Male; Middle Aged; Ondansetron; Radiothe | 1992 |
36 other studies available for ondansetron and Diarrhea
| Article | Year |
|---|---|
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
Topics: Animals; Carboxylic Acids; Castor Oil; Colon; Colonic Diseases, Functional; Defecation; Diarrhea; Di | 1993 |
[No place for ondansetron in young children with gastroenteritis and persistent vomiting].
Topics: Administration, Oral; Antiemetics; Child; Child, Preschool; Diarrhea; Double-Blind Method; Drug-Rela | 2022 |
Reduced sodium absorption in the colon under serotonin is a potential factor aggravating secretory diarrhea.
Topics: Animals; Colon; Diarrhea; Ondansetron; Rabbits; Serotonin; Sodium | 2023 |
Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer?
Topics: Diarrhea; Humans; Irritable Bowel Syndrome; Ondansetron; Receptors, Serotonin, 5-HT3; Serotonin | 2019 |
Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer? Authors' reply.
Topics: Diarrhea; Humans; Irritable Bowel Syndrome; Ondansetron; Receptors, Serotonin, 5-HT3; Serotonin | 2019 |
Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation?
Topics: Diarrhea; Double-Blind Method; Humans; Inflammation; Irritable Bowel Syndrome; Ondansetron | 2020 |
Reply to Black and Ford.
Topics: Diarrhea; Double-Blind Method; Humans; Irritable Bowel Syndrome; Ondansetron | 2021 |
Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea.
Topics: Diarrhea; Double-Blind Method; Humans; Irritable Bowel Syndrome; Ondansetron | 2021 |
Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child, Preschool; Diarrhea; Emergency Service, Hos | 2022 |
Electrocardiogram Challenge Syncope in a Woman With Nausea and Diarrhea.
Topics: Aged; Cholecalciferol; Clonazepam; Diarrhea; Esomeprazole; Female; Fluconazole; Humans; Nausea; Onda | 2017 |
Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial.
Topics: Administration, Oral; Antiemetics; Child, Preschool; Dehydration; Diarrhea; Double-Blind Method; Eme | 2019 |
Oral Ondansetron to Reduce Intravenous Fluid Rehydration: Context Matters.
Topics: Antiemetics; Child; Diarrhea; Emergency Service, Hospital; Fluid Therapy; Humans; Ondansetron; Pakis | 2019 |
Ondansetron for diarrhea associated with neuroendocrine tumors.
Topics: Diarrhea; Female; Humans; Intestinal Neoplasms; Liver Neoplasms; Male; Neuroendocrine Tumors; Ondans | 2013 |
Revival of 5-HT3 antagonism as treatment of IBS-D?
Topics: Diarrhea; Female; Humans; Irritable Bowel Syndrome; Male; Ondansetron; Serotonin Antagonists | 2014 |
Ondansetron and irritable bowel syndrome.
Topics: Diarrhea; Female; Humans; Irritable Bowel Syndrome; Male; Ondansetron; Serotonin Antagonists | 2015 |
The fall and rise of 5-hydroxytryptamine receptor antagonists in irritable bowel syndrome with diarrhea.
Topics: Diarrhea; Female; Humans; Irritable Bowel Syndrome; Male; Ondansetron; Serotonin Antagonists | 2014 |
An antiemetic for irritable bowel syndrome?
Topics: Diarrhea; Female; Humans; Irritable Bowel Syndrome; Male; Ondansetron; Serotonin Antagonists | 2014 |
Placebo-controlled Randomized Trial Evaluating Efficacy of Ondansetron in Children with Diarrhea and Vomiting: Critical Appraisal and Updated Meta-analysis: Evidence-based Medicine Viewpoint.
Topics: Antiemetics; Child; Diarrhea; Double-Blind Method; Evidence-Based Medicine; Humans; Ondansetron; Vom | 2016 |
Placebo-controlled Randomized Trial Evaluating Efficacy of Ondansetron in Children with Diarrhea and Vomiting: Critical Appraisal and Updated Meta-analysis: Pediatric Gastroenterologists Viewpoint.
Topics: Antiemetics; Child; Diarrhea; Double-Blind Method; Gastroenterologists; Humans; Ondansetron; Vomitin | 2016 |
Placebo-controlled Randomized Trial Evaluating Efficacy of Ondansetron in Children with Diarrhea and Vomiting: Critical Appraisal and Updated Meta-analysis: Pediatricians Viewpoint.
Topics: Antiemetics; Child; Diarrhea; Double-Blind Method; Humans; Ondansetron; Pediatricians; Vomiting | 2016 |
Emergency department management of gastro-enteritis in Australia and New Zealand.
Topics: Acute Disease; Antiemetics; Australia; Data Collection; Dehydration; Diarrhea; Emergency Medicine; E | 2008 |
Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging.
Topics: Adolescent; Adult; Aged; Diarrhea; Fasting; Female; Humans; Irritable Bowel Syndrome; Magnetic Reson | 2010 |
5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; | 2013 |
New benzimidazole derivatives: selective and orally active 5-HT3 receptor antagonists.
Topics: 5-Hydroxytryptophan; Administration, Oral; Animals; Aza Compounds; Behavior, Animal; Benzimidazoles; | 2003 |
Antiemetic use for gastroenteritis in children.
Topics: Acute Disease; Administration, Oral; Age Factors; Antiemetics; Child; Diarrhea; Emergency Treatment; | 2003 |
Ondansetron for acute gastroenteritis in children.
Topics: Acute Disease; Antiemetics; Child; Dehydration; Diarrhea; Fluid Therapy; Gastroenteritis; Humans; On | 2006 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |
Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine.
Topics: Antiemetics; Clonidine; Diarrhea; Humans; Indoles; Male; Malignant Carcinoid Syndrome; Middle Aged; | 1995 |
Ondasentron in the treatment of diabetic diarrhea.
Topics: Diabetes Mellitus, Type 1; Diabetic Neuropathies; Diarrhea; Glycated Hemoglobin; Humans; Male; Middl | 1994 |
Treatment of chronic cryptosporidiosis-induced diarrhea with a serotonin receptor antagonist.
Topics: Adult; AIDS-Related Opportunistic Infections; Cryptosporidiosis; Diarrhea; Humans; Male; Ondansetron | 1994 |
Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron.
Topics: Abdominal Pain; Adult; Diarrhea; Female; Humans; Nausea; Ondansetron; Prospective Studies | 1993 |
Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.
Topics: Adult; Aged; Diarrhea; Flushing; Gastric Emptying; Humans; Malignant Carcinoid Syndrome; Middle Aged | 1998 |
Secretory pathways in Salmonella Typhimurium-induced fluid accumulation in the porcine small intestine.
Topics: Analysis of Variance; Animals; Cholera Toxin; Diarrhea; Dinoprostone; Disease Models, Animal; Electr | 1998 |
Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine.
Topics: Animals; Antineoplastic Agents; Cisplatin; Diarrhea; Intestinal Absorption; Jejunum; Male; Ondansetr | 1999 |
Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Child; Constipation; Diarrhea; Drug Utilizatio | 2001 |
The involvement of 5-HT3 and 5-HT4 receptors in two models of gastrointestinal transit in mice.
Topics: 5-Hydroxytryptophan; Animals; Antidiarrheals; Croton Oil; Dermatologic Agents; Diarrhea; Gastrointes | 2002 |